Nektar Therapeutics

NKTR

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
SEC CIK: 0000906709

SEC filings (opens in a new tab)

In the last 90 days, Nektar Therapeutics insiders filed 0 open-market purchases and 2 sales; 239 institutions reported holding it in 13F filings for Q2 2026, worth $2.50B in total; no superinvestor holds it.

Q3 2024 vs. Q2 2024

How the institutions holding Nektar Therapeutics changed between Q2 2024 and Q3 2024.

All holders in Q3 2024 All holders in Q2 2024

13F holders of NKTR: Q2 2024 compared with Q3 2024
Measure	Q2 2024	Of which not filed for Q3 2024	Q3 2024	Change
Holders	135	1	140	+6
Shares	135.5M	15.2M	140.8M	+20.5M (+17.0%)
Value	$168.0M	$18.8M	$182.9M	+$33.8M (+22.6%)

1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.

New holders (23)

Institutions that held Nektar Therapeutics at the end of Q3 2024 but not at the end of Q2 2024.

Institutions new to NKTR in Q3 2024
Institution	Shares	Value	% of portfolio
BlackRock, Inc.	15,969,345	$20.8M	0.00%
Bridgeway Capital Management, LLC	1,362,100	$1.77M	0.04%
AQR Capital Management LLC	501,590	$627.0K	0.00%
Wellington Management Group LLP	473,090	$615.0K	0.00%
ExodusPoint Capital Management, LP	280,366	$364.0K	0.00%
Mirae Asset Global ETFs Holdings Ltd.	97,954	$127.3K	0.00%
Deutsche Bank AG	88,549	$115.1K	0.00%
ADAR1 Capital Management, LLC	67,754	$88.1K	0.01%
Manufacturers Life Insurance Company, The	66,218	$86.1K	0.00%
SEI Investments Co	62,498	$81.2K	0.00%
HB Wealth Management, LLC	44,500	$57.9K	0.00%
XTX Topco Ltd	35,170	$45.7K	0.00%
ProShare Advisors LLC	33,734	$43.9K	0.00%
Intech Investment Management LLC	31,249	$40.6K	0.00%
Valence8 US LP	26,107	$33.9K	0.01%
Neuberger Berman Group LLC	16,293	$21.2K	0.00%
Engineers Gate Manager LP	13,398	$17.4K	0.00%
Altium Capital Management LP	11,419	$14.8K	0.00%
CWM, LLC	3,355	$4.00K	0.00%
Sterling Capital Management LLC	567	$737	0.00%
Nisa Investment Advisors, LLC	317	$412	0.00%
Smartleaf Asset Management LLC	282	$329	0.00%
Capital Performance Advisors LLP	66	$86	0.00%

Sold out (17)

Institutions that held Nektar Therapeutics at the end of Q2 2024 and filed for Q3 2024 without it.

Institutions that sold out of NKTR in Q3 2024
Institution	Shares, Q2 2024	Value, Q2 2024
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main	187,385	$232.4K
Alpine Global Management, LLC	175,168	$217.2K
Virtu Financial LLC	75,063	$93.0K
Susquehanna International Group, LLP	64,928	$80.5K
Paloma Partners Management Co	55,229	$68.5K
Toroso Investments, LLC	42,500	$52.7K
US Asset Management LLC	37,861	$47.0K
Prospera Financial Services Inc	29,244	$36.3K
First Trust Investment Solutions L.P.	20,000	$24.8K
HighTower Advisors, LLC	18,608	$22.0K
Marathon Trading Investment Management LLC	16,877	$20.9K
Qube Research & Technologies Ltd	16,304	$20.2K
Franklin Street Advisors Inc	15,500	$19.0K
Picton Mahoney Asset Management	2,747	$3.00K
Atlas Capital Advisors LLC	600	$744
WealthCollab, LLC	300	$372
Princeton Global Asset Management LLC	100	$124

Not filed for Q3 2024 yet (1)

Institutions that held Nektar Therapeutics at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding NKTR in Q2 2024 that haven't filed for Q3 2024
Institution	Shares, Q2 2024	Value, Q2 2024
BlackRock Inc.	15,155,673	$18.8M